Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 17:19:1877-1884.
doi: 10.2147/OPTH.S523260. eCollection 2025.

Peripherex Home Visual Field Demonstrates High Test-Retest Reliability, Validity

Justin Schweitzer  1 , Mitch Ibach  1 , John Berdahl  1 , Myra Daoud  2 , Yahya A Daoud  2 , Yitzi Kempinski  3 , Jeffrey L Goldberg  4
Affiliations

Peripherex Home Visual Field Demonstrates High Test-Retest Reliability, Validity

Justin Schweitzer et al. Clin Ophthalmol. .

Abstract

Purpose: Assessment of disease and progression is one of the greatest unmet needs in glaucoma care. Moving visual field testing into the home stands to increase access and increase testing frequency to address these unmet needs. Here, we test a novel home-based app (Peripherex Visual Field Test or PRX-VFT) that leverages eye tracking in a short, "gamified" software environment, against in-office Humphrey Field Analyzer (HFA) data.

Methods: Observational, multicenter, open-label clinical trial in patients diagnosed with glaucoma, glaucoma suspect, or ocular hypertension.

Results: A total of 190 PRX tests were performed with 97 on the left eye and 93 on the right eye, derived from 36 eyes of 19 patients who also had reliable, matched HFA data. Patients were 58% female with a mean (SD) age of 61.5 (11.9) years (range 26-78). Test-retest reliability was good, with interclass correlation coefficient of 0.7596. Detection of abnormal fields was excellent, with a sensitivity of 95.7% and a negative predictive value (NPV) of 98.27%. Detection of normal fields was very good, with a specificity of 79.26% and a positive predictive value (PPV) of 66.36%. Patients reported that compared to HFA, PRX-VFT was easier and more fun to complete.

Conclusion: In-home visual field testing using PRX-VFT on a patient's personal computer met its primary clinical trial endpoints, was feasible, and showed excellent statistical correlation to in-office HFA testing. PRX-VFT represents an opportunity for enhancing patient care at minimal additional equipment cost to the patient or healthcare system.

Keywords: glaucoma; home healthcare; prospective clinical trial; visual field test.

Plain language summary

The Peripherex Visual Field Test (PRX VFT) uses a patient’s home computer or laptop with built-in eye tracking and patented algorithms. For this study, the PRX VFT was tested in the real-world, in-home setting, compared to in-office Humphrey visual field tests. The PRX VFT used at home showed excellent statistics against in-office testing, meeting primary endpoints in an IRB-approved multicenter clinical trial for FDA registration. These data support in-home use of the PRX VFT by the eye care provider for screening and monitoring in glaucoma, and may be extended to the screening and monitoring of other retinal, optic nerve and neurological diseases.

PubMed Disclaimer

Conflict of interest statement

Dr Mitch Ibach reports personal fees from Zeiss and Glaukos, outside the submitted work. Dr John Berdahl reports personal fees from AbbVie, Aerpio, ALJ Health, Alcon, Aldeyra, Aquea Health, Aurion Biotech, Avelino, Balance Opthalmics, Bausch & Lomb, Belkin, CorneaGen, Dakota Lions Eye Bank, Elios Vision Inc, Expert Opinion, Glaukos, Gore, Greenman, Horizon Surgical, Iacta Pharmaceuticals, Imprimis, iRenix, IVERIC Bio, Inc, J&J, Kala, LayerBio, MELT Pharmaceuticals, MicroOptx, New World Medical, Ocular Surgical Data, Ocular Therapeutix, Omega Opthalmic, Orasis, Oyster Point, RXSight, Santen, Sight Sciences, Surface Inc, Tarsus, TavoBio, Tear Clear, Tissue Gen, True North CRO, Vance Thompson Vision, Verana Health, Versea Biologics, Vertex Ventures, and ViaLase, outside the submitted work. Mr Yitzi Kempinski reports personal fees from Peripherex, Inc, outside the submitted work; In addition, Mr Yitzi Kempinski has a patent EP4504031A1 pending to Peripherex Inc, patents US9746918B2, US10254831B2 and US9911037B2 issued to Umoove Services Ltd. Dr Jeffrey Goldberg reports a patent 16/087,327 licensed to Peripherex, a patent 63/327,388 pending to Peripherex, and shares in Peripherex. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Example Peripherex visual field test screen showing the fixation target (blue) and a test stimulus (white) that is presented with variable brightness and contrast against a static background.
Figure 2
Figure 2
Example in-office Humphrey Field Analyzer visual field (HVF, left column) versus at-home Peripherex (PRX) visual field test in a patient’s fairly normal left eye (L, upper diagram; note x-axis inversion to simplify statistics) and more affected right (R, lower diagram) eye.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Zhang N, Wang J, Li Y, Jiang B. Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review. Sci Rep. 2021;11(1):13762. doi: 10.1038/s41598-021-92971-w - DOI - PMC - PubMed
    1. Gedde SJ, Vinod K, Wright MM, et al. Primary open-angle glaucoma preferred practice pattern(R). Ophthalmology. 2021;128(1):P71–P150. doi: 10.1016/j.ophtha.2020.10.022 - DOI - PubMed
    1. Phu J, Khuu SK, Nivison-Smith L, Kalloniatis M. Standard automated perimetry for glaucoma and diseases of the retina and visual pathways: current and future perspectives. Prog Retin Eye Res. 2025;104:101307. doi: 10.1016/j.preteyeres.2024.101307 - DOI - PubMed
    1. Beykin G, Goldberg JL. Molecular biomarkers for glaucoma. Curr Ophthalmol Rep. 2019;7(3):171–176. doi: 10.1007/s40135-019-00213-0 - DOI - PMC - PubMed
    1. Beykin G, Norcia AM, Srinivasan VJ, Dubra A, Goldberg JL. Discovery and clinical translation of novel glaucoma biomarkers. Prog Retin Eye Res. 2021;80:100875. doi: 10.1016/j.preteyeres.2020.100875 - DOI - PMC - PubMed

LinkOut - more resources